Physician profile
Christopher Brian Cave
NPI 1730169848
$10,274.58
in general payments reported to CMS, 2019-2025
45 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $1,073 · 2021: $2,071 · 2022: $2,164 · 2023: $1,672 · 2024: $947 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,070.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,737.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,558.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,544.93 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,042.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $830.32 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $495.37 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $310.78 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $308.83 | 2019-2023 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $214.87 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.30 | 2019-2025 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $160.48 | 2023 | Yupelri, Yupelri |
| Allergan, INC. | $154.28 | 2019-2020 | |
| Mannkind Corporation | $127.13 | 2022 | |
| Merck Sharp & Dohme LLC | $119.57 | 2019-2021 | |
| Amarin Pharma, INC. | $109.89 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.